Gut microbiota in esophageal cancer: mechanisms, clinical implications, and therapeutic potential
Open Access
- 5 October 2026
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17, 1955627
Abstract
Esophageal cancer (EC) is a highly prevalent and aggressive gastrointestinal malignancy. Late diagnosis and heterogeneous responses to chemoradiotherapy and immune checkpoint inhibitor (ICI) therapies severely challenge clinical management. Accumulating evidence suggests that gut microbiota dysbiosis influences esophageal mucosal malignant transformation, tumor progression, and therapeutic outcomes through the gut-esophageal axis. However, most existing research remains correlational. To bridge this gap, this review critically synthesizes the dysbiosis signatures of EC and establishes a five-tier evidence grading framework to rigorously distinguish causal mechanisms from preclinical inferences. This microbial regulation is predominantly driven by metabolite-mediated signaling, remodeling of the tumor immune microenvironment (TME), intestinal barrier disruption, and oncogenic pathway activation. We functionally classify EC-associated dysbiosis into pro-tumorigenic, anti-tumorigenic, and context-dependent taxa, emphasizing a multidimensional ecosystem perspective. Furthermore, we evaluate the utility of gut microbial signatures as predictive biomarkers for neoadjuvant therapy and prognosis. Microbiota-targeted intervention strategies, including fecal microbiota transplantation (FMT), microecological preparations, and Traditional Chinese Medicine (TCM), have entered clinical exploration as adjunctive approaches to optimize treatment efficacy. Finally, we address current translational barriers and propose future directions, emphasizing multi-omics integration, spatial transcriptomics, and artificial intelligence (AI). This provides an objective, mechanistically grounded framework for advancing microbiota-guided personalized oncology in EC.Keywords
This publication has 141 references indexed in Scilit:
- Stool Microbiome Features and Weight Change Response to Treatment for cancer cachexiaJournal of Cachexia, Sarcopenia and Muscle, 2025
- Current status and perspectives of esophageal cancer: a comprehensive reviewCancer Communications, 2024
- Disentangling the molecular mystery of tumour–microbiota interactions: Microbial metabolitesClinical and Translational Medicine, 2024
- Role of the Gut Microbiota and Its Metabolites in Tumorigenesis or Development of Colorectal CancerAdvanced Science, 2023
- The effect of Andrographis paniculata water extract on palliative management of metastatic esophageal squamous cell carcinoma—A phase II clinical trialPhytotherapy Research, 2023
- Progressive dysbiosis of human orodigestive microbiota along the sequence of gastroesophageal reflux, Barrett's esophagus and esophageal adenocarcinomaInternational Journal of Cancer, 2022
- Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumabInternational Journal of Cancer, 2022
- Network pharmacology reveals potential functional components and underlying molecular mechanisms of Andrographis paniculata in esophageal cancer treatmentPhytotherapy Research, 2022
- Review of the gut microbiome and esophageal cancer: Pathogenesis and potential clinical implicationsAnnals of Gastroenterological Surgery, 2017
- Randomized clinical trial of the effect of perioperative synbiotics versus no synbiotics on bacterial translocation after oesophagectomyBritish Journal of Surgery, 2014